Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

1234 Features
A Kidney Research UK study has proved that the Renal Services National Service Framework has had a positive impact in improving quality of care for the high-risk South Asian communities.

10 Feb 10

A recent research study, which was undertaken as part of medical research charity, Kidney Research UK’s ABLE programme, investigated the impact of national guidelines for the management of Chronic Kidney Disease (CKD), on referral patterns between South Asian and white European patients with type 2 diabetes mellitus (T2DM).
Kidney Research UK

How to | Use RSS to get a pharma job

27 Jan 10

RSS is a much under-estimated and under-used thing. It was originally conceived as an easy way of syndicating website content, hence the name “Really Simple Syndication”, but it now become a standard by which content is made available across the web to other sites or users.
Mike Wood

Haiti Aid

27 Jan 10

At 16:53 local time on Tuesday, 12 January 2010, the small Caribbean island nation of Haiti was dealt another cruel blow: a massive 7.0-magnitude earthquake struck at the heart of the nation - just over 15 miles west of the capital of Port-au-Prince. With the already traumatic history of this poor yet historic nation in mind, the events of January 12 represented yet another devastating hit to the already fragile foundations of this young nation.
Max Golby

Alzheimer’s - An Overview

21 Jan 10

Hardly a week goes by without Alzheimer’s being in the news – scientists discovering more about what causes it, developing a greater idea of how we can prevent or treat it, or another step being taken towards a cure.
Jackie Cosh, author of Alzheimer’s – The Essential Guide

Paying Off Competitors

14 Jan 10

Washington is famous for its lobbyists. Make no mistake, of all the industries currently making themselves heard on Capitol Hill, the healthcare lobby is one of the largest and the loudest. Indeed, according to the Center for Responsive Politics, the pharmaceutical industry had almost 1700 registered lobbyists in Washington as of late 2009. Unsurprisingly, then, the pharmaceutical industry has a considerable degree of pull on The Hill.
Max Golby

Gearing Up In 2010

23 Dec 09

This is the second of two articles written by Caroline Lock and Spencer Marsh at Only Medics Recruitment Ltd. In the last edition they looked at Recruitment 2010 and in this article they discuss Career Planning 2010.
Stephen Smith

Healthcare Reform

16 Dec 09

For over 75 years now, numerous Democratic Congressmen – and indeed several Presidents – have tried to pass something remotely resembling meaningful healthcare reform. For 75 years, they have failed. Back in 1993, Bill and Hillary Clinton’s failed ‘HillaryCare’ died with a whimper in the Senate and Mrs. Clinton was denied her chance at a second attempt by Mr. Obama in the Democratic primaries.
Max Golby

Swine Flu Update: 11/12/2009

10 Dec 09

Weekly Swine Flu Update for the Week Ending December 11th.
Max Golby

How to get experience and make the most of it.

08 Dec 09

‘You really need some more experience’. Perhaps the most ubiquitous phrase in modern day recruitment, thousands of graduates are now at the mercy of this one requirement as increasing competition in the job market leads to rising standards. Perhaps twenty, or even ten years ago, an undergraduate degree and a forceful sense of charisma might well have been enough to net you your first role in an industry.
Max Golby

ORBIS: what is it and how does it work?

08 Dec 09

Keynes called it an ‘inducement to invest’. In this instance, the most recent financial crisis has called for many of the same approaches used in the 1930s to stimulate the economy and bring industries back to their feet. Today more than ever, we realize that education is one of the most decisive facets of any successful stimulus.
Max Golby

USA, payments to Doctors – good, bad or ugly

08 Dec 09

At what point does a conflict of interests occur? Last year – and for many years before that – U.S. drugs companies paid out tens of millions of dollars in payments and gifts to physicians and academics. Earlier this year, the Pharmaceutical and Research Manufacturers of America (PhRMA) released a revised, and somewhat toughened, code of practice.
Max Golby

UK Visa’s and work permits – an overview for Pharma

07 Dec 09

Over the past year or so, the system for issuing VISAs and work permits in the UK has changed dramatically. A knowledge of the practical implications of the new system will be vital for anyone hoping to bring their skills to the pharmaceutical industry in this country
Max Golby

Halycon Days.. Are they over now - CSL's Perception

02 Dec 09

The phrase Halcyon days is a literary commonplace in the English language English language and culture, signifying ideals of prosperity, bonhomie, joy, liberation, or tranquility. I can testify to experiencing all these sentiments having worked in Clinical R&D for nearing 30 years. I'm not so certain we'll ever return to the same again though.
Ann Maloney BSc FICR

Top Ten Worst CV Mistakes!

26 Nov 09

I recently surveyed a range of pharmaceutical HR managers and recruiters to find out what they consider to be the worst errors you can make on your CV when applying for a pharma job. The results were quite surprising and funny at times, so I have compiled the following 10 point checklist to help you with your CV.
Mike Wood

Predicting a better future

19 Nov 09

At the Financial Times Global Pharmaceutical and Biotech Conference this week, the keynote address was given by M. Chris Viehbacher, Chief Executive Officer of Sanofi-aventis.
Paul Hartigan

PharmiWeb Solutions Talking to Jean-Luc Bélingard, CEO of Ipsen

17 Nov 09

We're having a fascinating day at the Financial Times Global Pharmaceutical and Biotechnology conference on London.
Paul Hartigan

Parallel imports – an overview for pharma

17 Nov 09

The craving for cheap drugs has never been greater. For those patients and policymakers in developing countries, the existence of parallel imports is less a concern than a blessing. Yet for pharmaceutical companies themselves, there is the concern that an increasing trade in parallel imports would severely damage research-intensive activities and ultimately slow down the development of the very same drugs that are being traded in ‘grey’ markets today.
Max Golby

Swine Flu Update: 02/11/2009

02 Nov 09

Weekly Swine Flu Update for the Week Ending November 1st.
Max Golby

Bogus Candidates in Recruitment?

28 Oct 09

A difficult economic climate breeds desperation. This is perhaps one of the most plausible explanations for the apparent behaviour of several unethical recruiters in the marketplace.
Max Golby - PharmiWeb Field Reporter

The Virtual Job Search

27 Oct 09

Whatever happened to the days of donning your best suit and tie and going out and looking for a job? Knocking on doors and meeting prospective employers, dazzling them with your wit, intelligence and enthusiasm. Unfortunately that is not possible in today’s society.
Trevor Abbott - PharmiWeb Field Reporter

IMPORTANT DECISIONS FOR PHARMA IN INDIA

16 Oct 09

In this edition of StrategicEdge, CBR Pharma Insights discusses some of the recent rulings by the Indian courts and their impact on the pharmaceutical industry's increasing interest in India.
CBR Pharma Insights

H1N1 Vaccine: It’s Arrived

13 Oct 09

Ever since the H1N1 virus first came onto the world map in April, ‘Where’s the vaccine?’ has been the cardinal question on everybody’s lips. As world governments scrambled to control the outbreak, supranational bodies such as the World Health Organization (WHO) threw themselves at the task of producing weekly updates for a virus which we originally knew very little about.
Max Golby

Swine Flu Update: 02/10/2009

01 Oct 09

Weekly Swine Flu Update for the Week Ending October 2nd.
Max Golby

HIV Vaccine: With New Hope Comes The Potential Dangers of Complacency

30 Sep 09

It is frightening because no one knows what's causing it, said a 28-year old law student who went to the St. Mark's Clinic in Greenwich Village last week complaining of swollen glands, thought to be one early symptom of the disease. Every week a new theory comes out about how you're going to spread it. - The New York Times , August 8th 1982.
Max Golby

ECCO-ESMO: Erbitux combined with FOLFIRI or FOLFOX4 significantly extends overall survival in advanced bowel cancer

28 Sep 09

A meta-analysis of the CRYSTAL and OPUS studies involving 845 patients with metastatic colorectal cancer (mCRC) tumours displaying the wild-type KRAS gene, has revealed first-line treatment with Erbitux (cetuximab) and FOLFOX4 or FOLFIRI chemotherapy significantly extends overall survival.
Olwen Glynn Owen

‘No Frills Drugs’ push Pharmaceutical companies to look for a cure

25 Sep 09

With the pharmaceutical industry heading into the well documented “expiry cliff” competition is rife. Quicker more cost effective methods of manufacturing must be found for big pharma to remain competitive and a clearer means of communication such as that seen at the NG Pharma Summit is clearly vital.
NG Online News

What does the multi-channel enabled pharma’ company look like?

17 Sep 09

Hardly a day goes by without a new report, today AT Kearney, last week Roland Berger and before them IMS and PWC warning of a gloomy future for pharmaceutical companies and saying that they must change their ways.
Paul Dixey, Managing Partner, BlueLight Partners

Medical Animation, Innovation and Communication

16 Sep 09

Medical animation is increasinlgy being employed by pharmaceutical companies to explain the scientific rationale behind their products.
Faiz Kermani

What Employers Really Want

16 Sep 09

In the eyes of many graduates, the economic recession has brought a new-found negativity to the job market. Thankfully, the climate is probably less dire than the situation sometimes imagined.
Max Golby

Can Schering-Plough’s asenapine improve prospects for schizophrenia and bipolar patients

16 Sep 09

More than half of schizophrenia patients are expected to relapse within two years if untreated and 4 out of 5 within five years, according to experts. Antipsychotics can reduce the relapse rate so long as patients continue on treatment. However, adherence is notoriously poor. A new antippsychotic – asenapine – shows promise of being effective and better tolerated.
Olwen Glynn Owen

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.